A chromatin remodeling checkpoint of diet-induced macrophage activation in adipose tissue

Dalamaga, Maria; Liu, Junli

doi:10.1016/j.metop.2022.100204

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that the severity of depressive symptoms may be associated with alterations in cytokine levels ( 30 ). Taken together the possible effect of age ( 31 ), gender, BMI ( 32 , 33 ), and smoking ( 34 ) on the serum cytokines, the relationship between the group and the abnormal cytokines was investigated in multiple linear regression models, with adjustments for age, gender, BMI, smoking, and HAMD-24 scores. The results revealed that group was a significant independent predictor of serum IL-17C, CCL-26, CXC10, VEGF, and TNF-β levels, further linking these cytokines to the SI of MDD patients.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood cytokines as potential diagnostic biomarkers of suicidal ideation in patients with first-episode drug-naïve major depressive disorder

Liang

Gao

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

ObjectiveMajor Depressive Disorder (MDD) is a leading cause of disability, with a high risk of suicidal ideation (SI). Few studies have evaluated the potential of multiple cytokines as biomarkers for SI in patients with MDD. In the present study, we examined the serum levels of multiple cytokines in patients with first-episode drug-naïve MDD, with the aim to discover and identify serum cytokines-based biomarkers for identification of SI in MDD.MethodsA total of 55 patients with first-episode drug-naïve MDD were enrolled and divided into two groups: 26 MDD patients without SI and 29 MDD patients with SI. Beck Scale for Suicide Ideation was used to estimate SI. A total of 37 cytokines were measured using Multiplex Luminex Assays. The levels of serum cytokines between MDD patients without SI and MDD patients with SI were compared and diagnostic values of different cytokines were evaluated using the receiver operating characteristic (ROC) curve method for discriminating MDD patients with SI from MDD patients without SI. The relationship between the group and the abnormal cytokines were investigated in multiple linear regression models, with adjustments for age, gender, BMI, smoking, and Hamilton Depression Rating Scale-24 (HAMD-24) scores.ResultsThe levels of CCL26 and VEGF in MDD patients with SI were significantly lower than those in MDD patients without SI (all P < 0.05). On the contrary, the levels of IL-17C, CXCL10, and TNF-β in MDD patients with SI were significantly higher than those in MDD patients without SI (all P < 0.05). Moreover, the results of multiple linear regression revealed that group was a significant independent predictor of serum IL-17C, CCL-26, VEGF, and TNF-β levels (all P < 0.05). In terms of CXC10, group was also likely to be a significant independent predictor (β = 0.257, P = 0.063). Furthermore, the AUC values of IL-17C and TNF-β were 0.728 and 0.732, respectively. Additionally, a combined panel of IL-17C and TNF-β achieved a high accuracy in discriminating MDD patients with SI from MDD patients without SI (AUC = 0.848, sensitivity = 75.9%, specificity = 72.7%).ConclusionsThese results suggested that circulating IL-17C and TNF-β may hold promise in the discovery of biomarkers for identification of SI in MDD.

show abstract

Section: Discussionmentioning

confidence: 99%

Peripheral blood cytokines as potential diagnostic biomarkers of suicidal ideation in patients with first-episode drug-naïve major depressive disorder

Liang

Gao

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Furthermore, SGLT-2 inhibitors reduce body weight by interfering with excess adipose tissue, which is known to synthesize inflammatory adipocytokines [28][29][30][31][32]. In obesity as well as in obesity-related disorders, such as NAFLD and T2DM, adipose tissue macrophages exhibit a polarization towards the M1 phenotype, which produces pro-inflammatory cytokines, such as Tumor Necrosis Factor alpha (TNF-α) and interleukin (IL)-6, thus, inducing a low-grade inflammatory state [33,34]. On the contrary, the M2 phenotype is restricted in obesity and obesity-related disorders, thereby, resulting in mitigation of the anti-inflammatory cytokines, such as IL-4 and IL-10 [35][36][37].…”

Section: Effects On Body Weight and Adiposity Indexesmentioning

confidence: 99%

SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?

Tsilingiris¹,

Kounatidis²,

Lempesis³

et al. 2022

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

As the tide of obesity and its complications is on the rise, there is an urgent need for new drugs with weight-lowering and beneficial metabolic properties. Obesity-related disorders, such as metabolic syndrome, prediabetes, type 2 diabetes mellitus (T2DM), cardiovascular disease and non-alcoholic fatty liver disease (NAFLD) make this need more than mandatory. Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) are the latest class of agents to receive approval for the treatment of T2DM. Not long after their marketing, a wide spectrum of target organ-protective and overall beneficial health effects associated with their use began to unveil. An increasing bulk of evidence points towards that these actions are to a great degree independent of glucose lowering, which has led to the broadening of the indications of SGLT-12 inhibitors outside the frame of antihyperglycemic therapy. Additionally, their unique mode of action including an increased renal glucose excretion and hence, net energy loss could render SGLT-2 inhibitors attractive candidates for the treatment of obesity. Very few reviews in the literature have appraised holistically the therapeutic potential of SGLT-2 inhibitors in obesity and its associated complications. Herein, we synopsize the currently available evidence regarding the effects of drugs of this class on body adiposity, together with considerations which accompany their potential use with the aim of weight loss. Furthermore, we attempt an overview of their actions and future perspectives of their use with respect to a range of obesity-related disorders, which include cardiovascular, renal, as well as NAFLD, malignancy, and ovarian dysfunction.

show abstract

“…Adipose tissue is now recognized as an active endocrine organ expressing and secreting a variety of cytokines that play parts in the pathogenesis of many obesity-related diseases ( 9 , 10 ). Obesity can be regarded as a state of chronic subclinical inflammation characterized by increased expression of proinflammatory cytokines, adipokines, and chemokines ( 11 , 12 ). It has been demonstrated that plasma levels of pro-inflammatory cytokines such as IL-6, tumor necrosis factor-α (TNF-α), and IL-1β were significantly higher in overweight individuals than normal-weight individuals ( 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Comparison of serum cytokines levels in normal-weight and overweight patients with first-episode drug-naïve major depressive disorder

Gao

Liang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveAbnormal levels of blood cytokines have been demonstrated to be associated with both excess weight and major depressive disorder (MDD). However, few studies have addressed the direct effect of body mass index (BMI) on basal serum cytokines in individuals with first-episode drug-naïve MDD.MethodsA total of 49 patients with first-episode drug-naïve MDD were categorized into normal weight (18.5 ≤ BMI < 25 kg/m2) and overweight (25 ≤ BMI < 30 kg/m2) groups according to WHO-criteria. The severity of depressive symptoms was assessed using the 24-items Hamilton Depression Scale (HAMD-24). A total of 37 cytokines were measured using Multiplex Luminex Assays. The scores of HAMD-24 and the levels of serum cytokines between normal weight group and overweight group were compared. Multiple linear regression analysis was performed to evaluate the association between abnormal serum cytokines levels and group after adjusting for HAMD-24 scores. The correlation between BMI and the scores of HAMD-24 and the levels of serum cytokines was evaluated using Pearson correlation analysis.ResultsThe scores of HAMD-24 in overweight group were significantly higher than normal weight group (t = -2.930, P = 0.005). Moreover, the levels of IL-1α, IL-1RA, IL-3, CXCL10, TNF-α, and ICAM-1 in overweight patients with MDD were significantly higher than those in normal-weight patients with MDD (all P < 0.05). Furthermore, after adjustment for HAMD-24 scores, there was a significant correlation between abnormal serum cytokines levels (IL-1α, IL-1RA, IL-3, CXCL10, TNF-α, and ICAM-1) and group (all P < 0.05). Additionally, BMI was positively correlated to the serum levels of IL-1α (r = 0.428, P = 0.002), IL-3 (r = 0.529, P < 0.001), IL-6 (r = 0.285, P = 0.050), IL-10 (r = 0.423, P = 0.003), IL-12 (r = 0.367, P = 0.010), IL-15 (r = 0.300, P = 0.036), CXCL10 (r = 0.316, P = 0.030), TNF-α (r = 0.338, P = 0.021), and ICAM-1 (r = 0.440, P = 0.002) in MDD patients.ConclusionsThese results provide direct evidence, probably for the first time, that overweight may be associated with several serum cytokines in patients with first-episode drug-naïve MDD. The underlying mechanisms are unclear and require further investigation.

show abstract

A chromatin remodeling checkpoint of diet-induced macrophage activation in adipose tissue

Cited by 6 publications

References 22 publications

Peripheral blood cytokines as potential diagnostic biomarkers of suicidal ideation in patients with first-episode drug-naïve major depressive disorder

Peripheral blood cytokines as potential diagnostic biomarkers of suicidal ideation in patients with first-episode drug-naïve major depressive disorder

SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?

Comparison of serum cytokines levels in normal-weight and overweight patients with first-episode drug-naïve major depressive disorder

Contact Info

Product

Resources

About